https://anzorpharma.com/anzor-pharmaceuticals-licenses-key-fibroblast-growth-factor-technology-from-new-york-university/2025-03-03T16:35:40+00:00https://anzorpharma.com/anzor-pharmaceuticals-to-present-at-chronic-kidney-disease-conference/2025-06-11T14:22:42+00:00https://anzorpharma.com/anzor-pharmaceuticals-selected-to-present-at-the-prestigious-biolabs-nyu-investor-innovator-exchange/2025-06-11T14:22:32+00:00https://anzorpharma.com/anzor-pharmaceuticals-receives-fda-orphan-drug-designation-for-fgf23-peptide-antagonist-in-treatment-of-x-linked-hypophosphatemia-xlh/2025-07-24T00:11:55+00:00https://anzorpharma.com/anzor-pharmaceuticals-announces-groundbreaking-patent-for-novel-%ce%b1-klotho-protein-therapy/2025-10-25T15:14:46+00:00